L ong-term follow-up was requested following the surprising finding that a single treatment with paclitaxel-coated balloons (PCB) reduced restenosis rates for 6 to 24 months in the femoropopliteal arteries both in randomized studies (1) (2) (3) (4) (5) and in single-arm studies (6) (7) (8) . Meanwhile 5-year follow-up of patients suffering from coronary instent restenosis treated with PCB is available (9) .
Follow-up data on the use of PCB in peripheral arteries have so far only been published for a maximum period 
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VOL. 8, NO. 1, 2015 STATISTICAL ANALYSIS. Statistical analysis was performed using SAS (version 9.2, SAS Institute Inc., Cary, North Carolina). In the patients available for 5-year FU, the incidence of first TLR overall and the incidence, intensity, and relationship to study treatment of serious adverse events (SAE) were analyzed as categorical or binary data. Data are presented as relative and absolute frequencies and were tested for group differences using the Fisher exact test.
Continuous data are presented as mean AE SD and were tested for group differences using a Wilcoxon rank sum test. 
Tepe et al. Follow-up data at 5 years were obtained from 66 patients (29 patients in the control group and 37 patients in the PCB group), whereas no data on the status of the study leg and/or death were available for a total of 20 of 102 patients (20%) (Figure 1 ).
With the exception of Rutherford stages, demographic data, risk factors, and baseline characteristics were well balanced between the 2 groups. At baseline, 85% of patients in the control group had Rutherford stage $3 as opposed to a total of 96% of patients in the PCB group. However, at 5-year Reasons for not performing the 5-year FU are listed. *1 study site dropped out (7 patients in the control group and 2 patients in the PCB group).
CM ¼ uncoated balloon plus paclitaxel in contrast medium; PCB ¼ paclitaxel-coated balloon; TLR ¼ target lesion revascularization.
Tepe et al.
The 
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Tepe et al. 0.7 mm in the PCB group, p ¼ 0.54) ( Table 2) .
Analysis of angiography and ultrasound findings as well as SAE revealed no evidence of aneurysm formation or other vascular abnormalities.
SEX ANALYSIS. In the explorative analysis of these data there was no difference in LLL at 6-month FU between women and men in the control (1.61 mm vs. 
DISCUSSION
The aim of the long-term FU of the THUNDER study was to assess the clinical efficacy of the PCB compared with that of the uncoated balloon based on the number of TLR. In addition, safety was assessed by analyzing SAE reported in the total patient cohort.
The intention of the angiographic or duplex ultrasound FU after 5 years was to detect possible side effects of PCB, which might not be reflected by the TLR rate (e.g., aneurysms). Because patients with >1
TLR already had several interventions prior to the 5-year FU, they were excluded from this additional analysis.
The present study was designed to measure angiographic LLL at 6-month FU and was not powered to assess angiographic and clinical outcomes up to 5 years after study intervention. However, the use of PCB resulted in reduced LLL, binary restenosis, and TLR rate at 5-year FU. Over this period, the cumulative number of patients with first TLR was distinctly lower in the PCB group than in the Abbreviations as in Figure 1 .
The THUNDER Trial 5 Years Later Using multiple PCB for treating long lesions might lead to higher local and systemic paclitaxel exposure and to a higher incidence of adverse events several years after treatment. However, peak plasma concentrations of paclitaxel shortly after the intervention were found to be below those known to cause systemic side effects (11) . No late thrombosis or formation of aneurysm was recorded in any patient up to 2 years after treatment (1). The incidence of SAE, major amputation rate, and death at the 5-year FU did not differ significantly between both groups.
Driven by the fact that the patients of the control group received more frequently more than 1 TLR during the first 24 months after the intervention, which was a pre-defined exclusion criterion for long- Values are n (% related to available patients/patients with data). *Differences between sexes are significant. STUDY LIMITATIONS. This randomized trial was powered on a 6-month angiographic primary endpoint. The 5-year FU was not prespecified in the study protocol. Therefore, the sample size is small for analysis of endpoints at 5-year FU and for subgroup analysis regarding sex and lesion length.
CONCLUSIONS
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